SCHEMBL4512985

SCHEMBL4512985

CC(=O)N1CCN(c2ccc(NC(=O)c3nnc(NC(=O)C4(c5ccc(Cl)cc5)CC4)o3)cc2)CC1

nearest known ligand 0.75

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 8/20 0.75
LMNA P02545 3/20 0.52
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
KMT2A Q03164 3/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MAPT P10636 4/20 0.46
HPGD P15428 2/20 0.46
MAPK1 P28482 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPKAPK2 P49137 1/20 0.46
MEN1 O00255 2/20 0.45
EP300 Q09472 1/20 0.45
ALDH1A1 P00352 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
USP2 O75604 1/20 0.44
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4506673 0.97 DGAT1 (0.81) DGAT1LMNANPC1RAB9AKMT2A
SCHEMBL4510806 0.97 DGAT1 (0.81) DGAT1LMNANPC1RAB9AKMT2A
SCHEMBL4496999 0.96 DGAT1 (0.80) DGAT1LMNANPC1RAB9AKMT2A
SCHEMBL4517504 0.91 DGAT1 (0.64) DGAT1LMNANPC1RAB9AKMT2A
SCHEMBL4511620 0.90 DGAT1 (0.61) DGAT1LMNANPC1RAB9AKMT2A
SCHEMBL4512056 0.88 DGAT1 (0.68) DGAT1LMNANPC1RAB9AKMT2A
SCHEMBL4507546 0.88 DGAT1 (0.67) DGAT1LMNANPC1RAB9AKMT2A
SCHEMBL4510050 0.87 DGAT1 (0.67) DGAT1LMNANPC1RAB9AKMT2A
SCHEMBL4510956 0.86 DGAT1 (1.00) DGAT1LMNANPC1RAB9AMAPT
SCHEMBL4494262 0.86 DGAT1 (1.00) DGAT1LMNANPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-08-27 US claimed
EP-1893592-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2008-03-05 EP claimed
WO-2006134317-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-12-21 WO claimed
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-08-27 US disclosed
EP-1893592-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2008-03-05 EP disclosed
WO-2006134317-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT2, GPR119, DGAT1 DGAT1 3/4885LMNA 3179/4885NPC1 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.